Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic immunoregulatory cytokine whose effects on arresting ‘random’ immune cell movement was already recognized decades ago. MIF is quasi-constitutively expressed by a variety of different cells and tissues, including immune cells such as T-cells and monocytes/macrophages, but also nonimmune cells like certain endocrine cells and cells lining interior body cavities or contacting the exterior environment, such as endothelial cells (ECs), or epithelial cells in kidney, gut and skin. Contrary to its historic name, MIF has a direct chemokine-like function and promotes ‘directed’ cell migration (i.e. chemotaxis) and plays a prominent role in inflammatory and atherogenic leukocyte recruitment. At the molecular level, these activities are based on a non-cognate interaction between MIF and the CXC chemokine receptors CXCR2 and CXCR4. Importantly, MIF also interacts with surface CD74, a type II transmembrane protein, inducing its phosphorylation and the recruitment of CD44, leading ultimately to ERK1/2 phosphorylation. Multiple studies have pointed to the utility of MIF as a biomarker for different diseases that have an inflammatory component; these include systemic infections and sepsis, cancer, autoimmune diseases as well as different metabolic disorders. In this Review, we highlight the suitability of MIF and CD74 as biomarkers for different disease applications.
Keywords: Biomarker, CD74, macrophage migration inhibitory factor (MIF), macrophage migration inhibitory factor receptor.
Mini-Reviews in Medicinal Chemistry
Title:MIF and CD74 - Suitability as Clinical Biomarkers
Volume: 14 Issue: 14
Author(s): Gerrit Grieb, Bong-Sung Kim, David Simons, Jurgen Bernhagen and Norbert Pallua
Affiliation:
Keywords: Biomarker, CD74, macrophage migration inhibitory factor (MIF), macrophage migration inhibitory factor receptor.
Abstract: Macrophage migration inhibitory factor (MIF) is a pleiotropic immunoregulatory cytokine whose effects on arresting ‘random’ immune cell movement was already recognized decades ago. MIF is quasi-constitutively expressed by a variety of different cells and tissues, including immune cells such as T-cells and monocytes/macrophages, but also nonimmune cells like certain endocrine cells and cells lining interior body cavities or contacting the exterior environment, such as endothelial cells (ECs), or epithelial cells in kidney, gut and skin. Contrary to its historic name, MIF has a direct chemokine-like function and promotes ‘directed’ cell migration (i.e. chemotaxis) and plays a prominent role in inflammatory and atherogenic leukocyte recruitment. At the molecular level, these activities are based on a non-cognate interaction between MIF and the CXC chemokine receptors CXCR2 and CXCR4. Importantly, MIF also interacts with surface CD74, a type II transmembrane protein, inducing its phosphorylation and the recruitment of CD44, leading ultimately to ERK1/2 phosphorylation. Multiple studies have pointed to the utility of MIF as a biomarker for different diseases that have an inflammatory component; these include systemic infections and sepsis, cancer, autoimmune diseases as well as different metabolic disorders. In this Review, we highlight the suitability of MIF and CD74 as biomarkers for different disease applications.
Export Options
About this article
Cite this article as:
Grieb Gerrit, Kim Bong-Sung, Simons David, Bernhagen Jurgen and Pallua Norbert, MIF and CD74 - Suitability as Clinical Biomarkers, Mini-Reviews in Medicinal Chemistry 2014; 14 (14) . https://dx.doi.org/10.2174/1389557515666150203143317
DOI https://dx.doi.org/10.2174/1389557515666150203143317 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry
Current Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Alternative Splicing and Tumor Progression
Current Genomics Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics S16020 Pyridocarbazole Derivatives Display High Activity to Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry New Advances of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery